Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran

authors:

avatar Seyed Moayed Alavian 1 , * , avatar Kamran B Lankarani 2 , avatar Seyed Hossein Aalaei-Andabili 1 , avatar Ali Pouryasin 3 , avatar Nasser Daryani 4 , avatar Mohsen Nasiritoosi 4 , avatar Reza Malekzadeh 5 , avatar Mohammad Reza Zali 6 , avatar Mino Mohraz 7

Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Islamic Azad University, Arsanjan Branch, Basic Science Faculty, Biology Department, Arsanjan, IR Iran
Tehran University of Medical Sciences, Tehran, IR Iran
Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran,, IR Iran
Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences, Tehran, IR Iran
Hepatitis Monthly: Vol.11, issue 9; e93018
published online: September 30, 2011
article type: Review Article
received: May 06, 2019
accepted: September 30, 2011

How To Cite Alavian S M, B Lankarani K, Aalaei-Andabili S H, Pouryasin A, Daryani N, et al. Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran. Hepat Mon. 2011;11(9):e93018. 

Abstract

Complete name and affiliation of collaborators are listed at the end of this article as an Appendix ( page: 711 ). 
Hepatitis C remains as an important health problem worldwide. Hepatitis C treatment, especially among patients infected with HCV genotype 1 who are considered difficult to treat, is a high priority for health policy-makers. PegInterferon alfa instead of Interferon and ribavirin combination therapy has been accepted as the standard treatment regimen for hepatitis C patients; however, only 50% of patients infected with HCV genotype 1 achieve a sustained virological response. Published data from various clinical trials of protease inhibitors suggest that new therapeutic regimens may increase the chances of a successful response in patients infected with HCV genotype 1. Triple therapy that includes boceprevir has been shown to result in high rates of sustained virological response in both naive and experienced patients with HCV genotype 1 infection. In this review, we have summarized the results obtained with this new regimen and have attempted to provide a guideline for the treatment of patients in Iran, with emphasis on cost and the occurrence of adverse events.
Implication for health policy/practice/research/medical education: 
Proper treatment of hepatitis C to control the burden of disease is essential in the society. Nowadays with the new methods of therapy the hope of eradication is more than before. This study is recommended to internal medicine and infectious disease specialists, gastroenterologists, general practitioners, virologists and health policy makers.
Please cite this paper as:
Alavian SM, Lankarani KB, Aalaei-Andabili SH, Pouryasin A, Ebrahimi Daryani N, Nassiri Toosi M, et al. Treatment of Chronic Hepatitis C Infection: Updated of the Recommendations from Scientific Leaders' Meeting-28th July 2011-Tehran, IR Iran. Hepat Mon. 2011; 11(9):703-13. DOI: 10.5812/kowsar.1735143X.769

References

  • 1.

    The references are available in the PDF file.